Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,480 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Failure Clear all
Recruiting Not applicable Interventional

Impact of Intraoperative Oxygenation Practices on Patient Outcomes

NCT07224243
View directory record Official record
Conditions
Surgeries Undergoing General Anesthesia
Interventions
Lower FiO2, Intermediate FiO2, Higher FiO2
Other
Lead sponsor
Frederic T Billings IV
Other
Eligibility
18 Years and older
Enrollment
54,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Ann Arbor, Michigan • Omaha, Nebraska • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional Results available

Genetic Testing to Understand and Address Renal Disease Disparities Across the United States

NCT04191824
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Timing of return of results
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
6,789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Not applicable Interventional Results available

The Impact of Nebivolol Versus Metoprolol on Quality of Life

NCT01441570
View directory record Official record
Conditions
Transplant; Failure, Kidney, Hypertension
Interventions
Nebivolol, Metoprolol succinate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 3 Interventional

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

NCT05021835
View directory record Official record
Conditions
Cardiovascular Risk, Chronic Kidney Disease, Inflammation
Interventions
Ziltivekimab B, Ziltivekimab C, Placebo (Ziltivekimab B), Placebo (Ziltivekimab C)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
6,385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
181
States / cities
Birmingham, Alabama • Montgomery, Alabama • Glendale, Arizona + 140 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Recruiting Not applicable Interventional

Accelerated Age-related Cognitive Decline: Impact of Exercise on Executive Function and Neuroplasticity

NCT05655325
View directory record Official record
Conditions
Mild Cognitive Impairment, Chronic Kidney Diseases
Interventions
Home-based walking exercise, Attention control
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired Renal Function

NCT06962774
View directory record Official record
Conditions
Renal Impairment
Interventions
ESK-001
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 20, 2026, 4:04 AM EDT
Active, not recruiting No phase listed Observational

AKI and Delirium Risk Prediction and Cost Burden Study

NCT07866560
View directory record Official record
Conditions
Acute Kidney Injury, Delirium
Interventions
It is observational trial with no intervention being evaluated
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
25,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D

NCT00977080
View directory record Official record
Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
Interventions
Paricalcitol, Cinacalcet
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
30
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional Results available

Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)

NCT01044303
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Myfortic Escalation
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1Phase 2 Interventional

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease

NCT01001351
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
PRT-201, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Fresno, California • San Diego, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational Results available

Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?

NCT02900170
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
60 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 1 Interventional

A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

NCT01170078
View directory record Official record
Conditions
Chronic Renal Failure
Interventions
Epoetin Hospira, Epogen
Drug
Lead sponsor
Hospira, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Downey, California • Tarzana, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 4 Interventional

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

NCT00073710
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
Zemplar, 42 Ca carbonate absorption via single tracer method, Calcijex
Drug · Procedure
Lead sponsor
Abbott
Industry
Eligibility
20 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational

Hemodialysis Vascular Access Imaging Study

NCT02374762
View directory record Official record
Conditions
Chronic Kidney Disease, Fistula, Hemodialysis Fistula Thrombosis
Interventions
Not listed
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 4 Interventional Results available

QUICKly Eradicate Hepatitis C in Patients Undergoing REnal Transplant With 4 Weeks of Glecaprevir/Pibrentasvir

NCT04515797
View directory record Official record
Conditions
Kidney Failure, Hepatitis C, Kidney Disease, Chronic
Interventions
Glecaprevir and Pibrentasvir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 20, 2026, 4:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

NCT06878560
View directory record Official record
Conditions
ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
Interventions
10 GE Xenokidney
Biological
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2075
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 20, 2026, 4:04 AM EDT
Not listed Not applicable Interventional

Study of an Intervention to Improve Problem List Accuracy and Use

NCT01105923
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer, Coronary Artery Disease, Congestive Heart Failure, Diabetes, Glaucoma, Hemophilia, Hypertension, Hyperthyroidism, Hypothyroidism, Myasthenia Gravis, Osteoporosis, Osteopenia, Renal Failure, Renal Insufficiency, Sickle Cell Disease, Stroke
Interventions
MAPLE
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2015 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional Results available

Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)

NCT00001959
View directory record Official record
Conditions
Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions
Pirfenidone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Phase 2 Interventional

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction

NCT00119691
View directory record Official record
Conditions
Congestive Heart Failure, Renal Insufficiency
Interventions
Nesiritide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional

Maximizing Acute Kidney Injury End-point Intervention Post-Discharge (MAKE-IT) Study

NCT04358874
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Medication reconciliation, Blood Pressure Management
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Birmingham, Alabama • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Phase 3 Interventional Results available

Pediatric Chronic Kidney Disease Safety and Efficacy

NCT01277510
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
Interventions
cinacalcet capsule, placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 20, 2026, 4:04 AM EDT
Completed Not applicable Interventional Results available

Pilot Study to Evaluate Safety, Tolerability, and Performance of the FAST PV Technology™ in Chronic Dialysis Patients

NCT04733664
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
VFI using the FAST PV Technology
Device
Lead sponsor
FAST BioMedical
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 20, 2026, 4:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)

NCT02105298
View directory record Official record
Conditions
Respiratory Failure, Acute Respiratory Failure Requiring Reintubation, Pulmonary Edema, Pneumonia, Hypoxia, Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
104,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2015 · Synced Oct 20, 2026, 4:04 AM EDT
Terminated Not applicable Interventional

A Study Looking at the Use of Biomarkers to Provide Early Indication of Acute Kidney Injury in Patients With Sepsis (Limiting AKI Progression In Sepsis)

NCT04434209
View directory record Official record
Conditions
Sepsis, Acute Kidney Injury, Septic Shock
Interventions
Subject management guided by NephroCheck® test, Standard of Care
Device · Other
Lead sponsor
BioMérieux
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Shreveport, Louisiana • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 20, 2026, 4:04 AM EDT